Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1989 Nov;60(5):734–738. doi: 10.1038/bjc.1989.349

Anti-inflammation induced by counter-irritation or by treatment with non-steroidal agents inhibits the growth of a tumour of non-detected immunogenicity.

D O Sordelli 1, P A Fontán 1, R P Meiss 1, R A Ruggiero 1, O D Bustuoabad 1
PMCID: PMC2247308  PMID: 2803950

Abstract

Counter-irritation (CI) triggered by different non-specific irritant stimuli delayed the growth of a murine tumour of non-detected immunogenicity. The syngeneic LB tumour transplant by itself also induced CI and decreased the number of leukocytes migrating to a secondary s.c. irritant stimulus, e.g. sponge or carrageenan. On the other hand, partial inhibition of cell migration by treatment with either 0.5 mg kg-1 indomethacin or 0.3 mg kg-1 piroxicam retarded LB tumour growth, presumably by a mechanism unrelated to inhibition of immune responses by PGE2. It is suggested that CI may play a role in the early stages of concomitant resistance.

Full text

PDF
734

Images in this article

736Figure 5
on p.736

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atkinson D. C., Hicks R. The anti-inflammatory activity of irritants. Agents Actions. 1975 Aug;5(3):239–249. doi: 10.1007/BF02026438. [DOI] [PubMed] [Google Scholar]
  2. Attia M. A., Weiss D. W. Immunology of spontaneous mammary carcinomas in mice. V. Acquired tumor resistance and enhancement in strain A mice infected with mammary tumor virus. Cancer Res. 1966 Aug;26(8):1787–1800. [PubMed] [Google Scholar]
  3. Barrera C. N., Mazzolli A. B., Bustuoabad O. D., Andreetta A. M., Pasqualini C. D. Macrophages and tumor growth. II. Cell kinetics at the site of allogeneic tumor growth. Cancer Invest. 1985;3(1):7–13. doi: 10.3109/07357908509040603. [DOI] [PubMed] [Google Scholar]
  4. Bennett A., Berstock D. A., Carroll M. A. Increased survival of cancer-bearing mice treated with inhibitors of prostaglandin synthesis alone or with chemotherapy. Br J Cancer. 1982 May;45(5):762–768. doi: 10.1038/bjc.1982.118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bennett A., Carroll M. A., Melhuish P. B., Stamford I. F. Treatment of mouse carcinoma in vivo with a prostaglandin E2 analogue and indomethacin. Br J Cancer. 1985 Aug;52(2):245–249. doi: 10.1038/bjc.1985.184. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bennett A., Houghton J., Leaper D. J., Stamford I. F. Cancer growth, response to treatment and survival time in mice: beneficial effect of the prostaglandin synthesis inhibitor flurbiprofen. Prostaglandins. 1979 Feb;17(2):179–191. doi: 10.1016/0090-6980(79)90037-6. [DOI] [PubMed] [Google Scholar]
  7. Braun D. P., Bonomi P. D., Taylor S. G., 4th, Harris J. E. Modification of the effects of cytotoxic chemotherapy on the immune responses of cancer patients with a nonsteroidal, antiinflammatory drug, piroxicam. A pilot study of the Eastern Cooperative Oncology Group. J Biol Response Mod. 1987 Jun;6(3):331–345. [PubMed] [Google Scholar]
  8. Caignard A., Martin M., Reisser D., Thomas B., Martin F. Effects of cimetidine and indomethacin on the growth of dimethylhydrazine-induced or transplanted intestinal cancers in the rat. Br J Cancer. 1984 Nov;50(5):661–665. doi: 10.1038/bjc.1984.233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Folkman J., Cotran R. Relation of vascular proliferation to tumor growth. Int Rev Exp Pathol. 1976;16:207–248. [PubMed] [Google Scholar]
  10. Folkman J. Tumor angiogenesis. Adv Cancer Res. 1985;43:175–203. doi: 10.1016/s0065-230x(08)60946-x. [DOI] [PubMed] [Google Scholar]
  11. Fulton A. M. In vivo effects of indomethacin on the growth of murine mammary tumors. Cancer Res. 1984 Jun;44(6):2416–2420. [PubMed] [Google Scholar]
  12. Goodwin J. S., Ceuppens J. Regulation of the immune response by prostaglandins. J Clin Immunol. 1983 Oct;3(4):295–315. doi: 10.1007/BF00915791. [DOI] [PubMed] [Google Scholar]
  13. Gorelik E., Segal S., Feldman M. On the mechanism of tumor "concomitant immunity". Int J Cancer. 1981 Jun 15;27(6):847–856. doi: 10.1002/ijc.2910270618. [DOI] [PubMed] [Google Scholar]
  14. Humes J. L., Cupo J. J., Jr, Strausser H. R. Effects of indomethacin on Moloney sarcoma virus-induced tumors. Prostaglandins. 1974 Jun 25;6(6):463–473. doi: 10.1016/s0090-6980(74)80056-0. [DOI] [PubMed] [Google Scholar]
  15. Kort W. J., Hulsman L. O., van Schalkwijk W. P., Weijma I. M., Zondervan P. E., Westbroek D. L. Reductive effect of aspirin treatment on primary tumor growth and metastasis of implanted fibrosarcoma in rats. J Natl Cancer Inst. 1986 Apr;76(4):711–720. doi: 10.1093/jnci/76.4.711. [DOI] [PubMed] [Google Scholar]
  16. Lynch N. R., Castes M., Astoin M., Salomon J. C. Mechanism of inhibition of tumour growth by aspirin and indomethacin. Br J Cancer. 1978 Oct;38(4):503–512. doi: 10.1038/bjc.1978.237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. McCormick D. L., Madigan M. J., Moon R. C. Modulation of rat mammary carcinogenesis by indomethacin. Cancer Res. 1985 Apr;45(4):1803–1808. [PubMed] [Google Scholar]
  18. McCormick D. L., Moon R. C. Inhibition of mammary carcinogenesis by flurbiprofen, a non-steroidal antiinflammatory agent. Br J Cancer. 1983 Dec;48(6):859–861. doi: 10.1038/bjc.1983.278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Meiss R. P., Bonfil R. D., Ruggiero R. A., Pasqualini C. D. Histologic aspects of concomitant resistance induced by nonimmunogenic murine tumors. J Natl Cancer Inst. 1986 Jun;76(6):1163–1175. [PubMed] [Google Scholar]
  20. Narisawa T., Sato M., Tani M., Kudo T., Takahashi T., Goto A. Inhibition of development of methylnitrosourea-induced rat colon tumors by indomethacin treatment. Cancer Res. 1981 May;41(5):1954–1957. [PubMed] [Google Scholar]
  21. Normann S. J., Schardt M., Sorkin E. Antileukocyte activity I. Systemic inhibition of cellular emigration following local inflammation. J Leukoc Biol. 1985 Mar;37(3):319–330. doi: 10.1002/jlb.37.3.319. [DOI] [PubMed] [Google Scholar]
  22. Normann S. J., Schardt M., Sorkin E. Antileukocyte activity II. Induction of tolerance to systemic anti-inflammation associated with local irritation and major surgery. J Leukoc Biol. 1985 Mar;37(3):331–339. doi: 10.1002/jlb.37.3.331. [DOI] [PubMed] [Google Scholar]
  23. Normann S., Besedovsky H., Schardt M., del Rey A. Hormonal changes following tumor transplantation: factors increasing corticosterone and the relationship of corticosterone to tumor-induced anti-inflammation. Int J Cancer. 1988 Jun 15;41(6):850–854. doi: 10.1002/ijc.2910410613. [DOI] [PubMed] [Google Scholar]
  24. Normann S., Schardt M., Sorkin E. Cancer induced anti-inflammation and its potentiation by tumor excision and rechallenge. J Leukoc Biol. 1987 Jul;42(1):61–68. doi: 10.1002/jlb.42.1.61. [DOI] [PubMed] [Google Scholar]
  25. Oyanagui Y. Anti-inflammatory effects of polyamines in serotonin and carrageenan paw edemata - possible mechanism to increase vascular permeability inhibitory protein level which is regulated by glucocorticoids and superoxide radical. Agents Actions. 1984 Feb;14(2):228–237. doi: 10.1007/BF01966647. [DOI] [PubMed] [Google Scholar]
  26. Panje W. R. Regression of head and neck carcinoma with a prostaglandin-synthesis inhibitor. Arch Otolaryngol. 1981 Nov;107(11):658–663. doi: 10.1001/archotol.1981.00790470006003. [DOI] [PubMed] [Google Scholar]
  27. Pollard M., Luckert P. H. Effect of indomethacin on intestinal tumors induced in rats by the acetate derivative of dimethylnitrosamine. Science. 1981 Oct 30;214(4520):558–559. doi: 10.1126/science.7291992. [DOI] [PubMed] [Google Scholar]
  28. Pollard M., Luckert P. H., Schmidt M. A. The suppressive effect of piroxicam on autochthonous intestinal tumors in the rat. Cancer Lett. 1983 Nov;21(1):57–61. doi: 10.1016/0304-3835(83)90082-4. [DOI] [PubMed] [Google Scholar]
  29. Prehn R. T., Prehn L. M. The autoimmune nature of cancer. Cancer Res. 1987 Feb 15;47(4):927–932. [PubMed] [Google Scholar]
  30. Reddy B. S., Maruyama H., Kelloff G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res. 1987 Oct 15;47(20):5340–5346. [PubMed] [Google Scholar]
  31. Robertson B., Dostal K., Daynes R. A. Neuropeptide regulation of inflammatory and immunologic responses. The capacity of alpha-melanocyte-stimulating hormone to inhibit tumor necrosis factor and IL-1-inducible biologic responses. J Immunol. 1988 Jun 15;140(12):4300–4307. [PubMed] [Google Scholar]
  32. Rubio C. A. Antitumoral activity of indomethacin on experimental esophageal tumors. J Natl Cancer Inst. 1984 Mar;72(3):705–707. [PubMed] [Google Scholar]
  33. Ruggiero R. A., Bustuoabad O. D., Bonfil R. D., Meiss R. P., Pasqualini C. D. "Concomitant immunity" in murine tumours of non-detectable immunogenicity. Br J Cancer. 1985 Jan;51(1):37–48. doi: 10.1038/bjc.1985.6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Shin H. S., Hayden M., Langley S., Kaliss N., Smith M. R. Antibody-mediated suppression of grafted lymphoma. III. Evaluation of the role of thymic function, non-thymus-derived lymphocytes, macrophages, platelets, and polymorphonuclear leukocytes in syngeneic and allogeneic hosts. J Immunol. 1975 Apr;114(4):1255–1263. [PubMed] [Google Scholar]
  35. Snyderman R., Pike M. C., Blaylock B. L., Weinstein P. Effects of neoplasms on inflammation: depression of macrophage accumulation after tumor implantation. J Immunol. 1976 Mar;116(3):585–589. [PubMed] [Google Scholar]
  36. Zbar B., Wepsic H. T., Rapp H. J., Stewart L. C., Borsos T. Two-step mechanism of tumor graft rejection in syngeneic guinea pigs. II. Initiation of reaction by a cell fraction containing lymphocytes and neutrophils. J Natl Cancer Inst. 1970 Mar;44(3):701–717. [PubMed] [Google Scholar]
  37. Ziche M., Jones J., Gullino P. M. Role of prostaglandin E1 and copper in angiogenesis. J Natl Cancer Inst. 1982 Aug;69(2):475–482. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES